Stenotrophomonas maltophilia is a bacteria which is resistant to several antibiotics. Over the last 10 years this bacteria has increasingly been found in the lungs of people with cystic fibrosis. Chronic infection with Stenotrophomonas maltophilia has been found to be linked to pulmonary infections. However, at present, it is unclear if people with cystic fibrosis should be treated for this bacteria when it is grown in their lungs. The purpose of this review is to determine if treatment with different antibiotic combinations for Stenotrophomonas maltophilia will improve lung function or decrease the frequency of hospital admission in people with cystic fibrosis. We also want to review the effect of treatment of chronic Stenotrophomonas maltophilia infection in order to clear this bacteria from the lungs of a person with cystic fibrosis. We did not find any randomized controlled trials which we could include in the review. We did find one trial of antibiotic treatment for pulmonary exacerbations which included patients with Stenotrophomonas maltophilia, but the patients in the trial also had infections caused by other bacteria and we were not able to obtain data separately for the different causes of infection. Randomized controlled trials are needed to inform clinicians as to whether they should treat Stenotrophomonas maltophilia infection in people with cystic fibrosis. In the meantime, clinicians should use their clinical judgement when considering this question.
Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis
2 April 2014
More like this
- Which antibiotics are best to treat worsening symptoms in people with cystic fibrosis with persistent Burkholderia cepacia complex lung infection?
- Inhaling antibiotics to treat temporary worsening of lung infection in people with cystic fibrosis
- Antibiotic treatment for nontuberculous mycobacteria in people with cystic fibrosis
- Oral antibiotics for treating infection with Pseudomonas aeruginosa in people with cystic fibrosis
- A comparison of single and combined intravenous drug therapy for people with cystic fibrosis